Body Pharm BPC-157 + TB-500

A BPC-157 + TB-500 blend research pen is a pre-filled, multi-dose injection device combining two regenerative peptides in one cartridge, sold in the UK for in vitro and laboratory research use only. Neither BPC-157 nor TB-500 is scheduled under the Misuse of Drugs Act 1971, though both sit on the WADA (World Anti-Doping Agency) Prohibited List as growth factors [5]. This page explains why the pen format outperforms separately sourced vials, details batch traceability procedures, and sets out the 2026 UK regulatory position before checkout. Comparable UK blends from OP Labs, Regen Peptides and Tide Labs ship as 10 mg total (5 mg + 5 mg) reconstitution vials [1][2][3]; the pen removes the reconstitution step entirely.

Key Takeaways

• A sealed BPC-157 + TB-500 pen delivers a fixed peptide ratio per dose, eliminating reconstitution error and ratio drift across two separate vials
• Both peptides are unscheduled under UK drugs law but unlicensed for human use; the pen is sold strictly for research use
• Batch traceability is built in: every pen carries a unique batch number linked to HPLC purity data, mass-spec identity confirmation, and a Certificate of Analysis
• The pen format removes manual mg-to-volume calculation, the single largest source of dose variance in vial-based blend work
• Pre-measured delivery reduces inter-operator drift across multi-week research studies

What Is the BPC-157 + TB-500 Blend?

A BPC-157 + TB-500 blend is a single-cartridge combination of two synthetic regenerative peptides: BPC-157, a 15-amino-acid pentadecapeptide derived from a protective sequence in human gastric juice, and TB-500, a synthetic fragment of the 43-amino-acid protein Thymosin Beta-4. UK researchers buy the blend to study complementary tissue-repair pathways without the reconstitution step.

BPC-157: the gastric-derived pentadecapeptide

BPC-157 (Body Protection Compound-157) is a stable synthetic pentadecapeptide of 15 amino acids, originally isolated from a larger protective protein found in gastric juice. Preclinical work, predominantly from Sikiric and colleagues, has examined its activity in gastrointestinal ulcer models, tendon and ligament repair models, and endothelial/VEGF (vascular endothelial growth factor)-linked angiogenesis pathways. No large human trial has yet clarified its in vivo mechanism, a translational gap flagged in current commentary [6].

TB-500: the Thymosin Beta-4 analogue

TB-500 is a synthetic analogue or fragment of Thymosin Beta-4, a 43-amino-acid actin-sequestering protein involved in cell migration, angiogenesis, and wound healing [5]. The precise sequence and molecular weight of the TB-500 fragment vary by supplier and are not separately published for every UK product; the wider research-chemical market typically references a Thymosin Beta-4-derived fragment in the 4.9–5.1 kDa range [unverified].

Why researchers combine them

The two peptides target mechanistically distinct pathways. BPC-157 is most heavily studied in gastric and connective-tissue models; TB-500 work focuses on systemic actin regulation and angiogenesis. For experimental designs that need both axes covered in parallel, see our full BPC-157 + TB-500 dosing protocol and the BPC-157 vs TB-500: how the two peptides compare guide.

Why a Combined Pen Beats Separate Vials

A pre-combined BPC-157 + TB-500 pen removes the largest sources of dose variance in a research run: reconstitution error, ratio drift, and storage degradation across two open vials. The practical effect is a fixed peptide ratio per click, which is the single biggest determinant of inter-session reproducibility when two peptides are co-administered.

Reconstitution error compounds across two vials

Manual reconstitution of two separate lyophilised vials introduces compounding pipetting tolerances. Each transfer of bacteriostatic water, each vial swirl, and each draw into a syringe carries a small volumetric variance, commonly estimated at ±5–10% per step in non-calibrated lab work [estimate, unverified]. Run that twice, once for BPC-157, once for TB-500, and the effective ratio at the point of injection can drift well outside the intended design.

In our fill-and-seal process, both peptides are co-dissolved against a single validated diluent volume before the pen is sealed. The ratio is set once, under controlled conditions, rather than re-established by the end user before every dose.

Ratio consistency and stability

A sealed pen delivers a fixed BPC-157:TB-500 ratio per click for the life of the cartridge. This allows a research team to compare week-three data to week-one data without re-validating the prep. Two separately opened vials, by contrast, are exposed to repeated septum punctures, ambient temperature excursions during handling, and the cumulative oxidative load that comes with each reconstitution event. No competing UK vendor we have surveyed currently publishes this reconstitution-error argument in product copy [original observation, 2026].

For dose-per-click guidance and a worked ratio example, see our full BPC-157 + TB-500 dosing protocol, and for mechanism-level rationale behind the pairing, the BPC-157 vs TB-500: how the two peptides compare guide.

Body Pharm BPC-157 + TB-500 Pen: Product Specification

The Body Pharm BPC-157 + TB-500 pen is a pre-mixed, sealed research injection device containing both peptides co-dissolved at a fixed ratio, supplied with a batch-specific Certificate of Analysis and shipped under refrigerated conditions for UK research use only. Each pen is intended for click-dosed administration without end-user reconstitution.

Spec table

What the Certificate of Analysis covers

Every batch ships with a CoA documenting HPLC (High-Performance Liquid Chromatography) purity for both peptides, mass spectrometry confirmation of sequence identity, appearance, and residual solvent screening. Endotoxin testing is performed where the batch is designated for sterile-fill workflows. CoAs are issued against internal quality procedures aligned with EU GMP (Good Manufacturing Practice) Annex 1 principles for sterile product handling [unverified].

For ratio maths and per-click examples, see the full BPC-157 + TB-500 dosing protocol; for mechanism-level background, the BPC-157 vs TB-500: how the two peptides compare guide covers sequence and pathway detail.

Quality, Purity & Batch Traceability

Every pen we dispatch is traceable from fill line to courier label via a unique batch number printed on the device and repeated on its Certificate of Analysis. In our batch-handling process, each fill run is sealed under controlled conditions at the originating EU laboratory, dose-validated by click-count check on a sampled subset, and released only once the CoA is countersigned against internal specifications aligned with EU GMP Annex 1 principles for sterile product handling [unverified]. Researchers can request the full batch file (CoA, originating lab name, fill date) by quoting the batch number to our support desk.

What HPLC purity actually tells you

High-Performance Liquid Chromatography separates the peptide from synthesis by-products, truncated sequences, and residual solvents, then quantifies each fraction. A purity figure of, say, ≥98% means at least 98% of the detected mass corresponds to the intended peptide; the remaining ≤2% is characterised impurities. For BPC-157 + TB-500 blends, both peptides are assayed individually so a single "blend purity" number cannot mask one weak component. Competing UK vendors typically advertise ≥99% HPLC purity on comparable blends [1][2]; the HPLC purity threshold for each batch is disclosed on its Certificate of Analysis.

Accessing your batch documentation

Quote the batch code at checkout or email it post-delivery and we return the CoA PDF, including HPLC chromatograms and mass-spec identity confirmation, within one working day. For protocol-side decisions once the CoA is in hand, the full BPC-157 + TB-500 dosing protocol walks through per-click maths.

UK Regulatory Context: Research Use Only

BPC-157 and TB-500 are not licensed medicines in the United Kingdom and are not approved by the MHRA (Medicines and Healthcare products Regulatory Agency) for human use; they are sold here strictly as research chemicals for in vitro and analytical work. As of 2026, neither peptide is named in the schedules of the Misuse of Drugs Act 1971 or its associated Misuse of Drugs Regulations [unverified], so they are not controlled drugs. They fall instead under the general remit of the Human Medicines Regulations 2012, which is why unlicensed injectable preparations cannot lawfully be supplied for human administration regardless of "research use only" labelling [3][4].

This distinguishes the pen from any licensed pharmaceutical product dispensed through a UK pharmacy: there is no Marketing Authorisation, no SmPC (Summary of Product Characteristics), and no patient information leaflet. Both peptides are also on the WADA Prohibited List under growth factors, which is relevant to sport but separate from MHRA scheduling [1]. Purchasers responsible for institutional compliance should verify their research-governance framework before ordering.

Body Pharm supplies verified research buyers only. If you are still comparing the two peptides before committing, the BPC-157 vs TB-500 comparison guide sits alongside this product page.

Disclaimer: This product is sold for laboratory research and analytical reference use only. Not for human or veterinary consumption, not for diagnostic use, and not for in vivo administration. No therapeutic claims are made or implied.

Shipping, Packaging & Returns

UK orders ship free via tracked Royal Mail, typically arriving within 1–3 working days. Every parcel goes out in plain, unbranded outer packaging, and you receive a tracking number by email at dispatch so procurement can reconcile delivery against the batch reference on the pen.

Returns are accepted on unused, unopened items within 14 days of delivery. Once a pen has been opened or the tamper seal broken, it cannot be returned, standard practice for sterile research consumables. If a parcel arrives damaged in transit, photograph the outer and inner packaging before opening and contact us within 48 hours so we can arrange a replacement against the same batch where stock allows.

Cold-chain handling for transit is arranged according to destination and transit time. International shipping availability and duties are calculated at checkout by destination.

Researchers still finalising protocol parameters can cross-reference the full BPC-157 + TB-500 dosing protocol before placing the order.

BPC-157 vs TB-500: How They Differ and Why Combine Them

BPC-157 and TB-500 are studied together because they act through distinct mechanisms that researchers hypothesise to be complementary rather than redundant. BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric protective sequence, with a molecular weight of approximately 1,419 Da, and is most often investigated in connective-tissue, tendon, and gastrointestinal models where angiogenic and nitric-oxide-pathway effects dominate the literature [5]. TB-500 is a synthetic fragment associated with Thymosin Beta-4 (parent protein ~4,964 Da; confirm exact fragment MW with the product team), studied for systemic effects on actin sequestration, cell migration, and vascular development [6].

The rationale for the blend is pathway separation: local connective-tissue activity from BPC-157 alongside systemic actin-regulatory activity from TB-500. For the full mechanistic breakdown, see our BPC-157 vs TB-500: how the two peptides compare guide.

Dosing Guidance for Research Protocols

The pen dials the dose directly, removing the manual mg-to-volume calculation step that introduces the largest source of variability in vial-based blend work. Because both peptides are co-dissolved 50/50, the figure you dial is the dose of each peptide and the total delivered is double it. For full protocol detail, including the dial-to-dose mapping and research administration schedules, see our full BPC-157 + TB-500 dosing protocol.

In our batch-handling workflow, pre-measured delivery has two practical consequences for reproducibility: dose-to-dose variance is constrained by the device mechanism rather than by pipetting technique, and inter-operator drift across a multi-week study window is meaningfully reduced. The pen is pre-filled and dialled directly in milligrams, so existing SOPs (Standard Operating Procedures) built around lyophilised blends can drop the reconstitution steps entirely.

This product is supplied strictly for in vitro and laboratory research use. Nothing on this page constitutes dosing advice for human or veterinary administration, and the linked guide is written for research protocol design only.

Frequently Asked Questions

Is BPC-157 + TB-500 legal to buy in the UK?

Yes, for laboratory research use. Neither peptide is a controlled substance under the Misuse of Drugs Act 1971 or current statutory instruments, and supply is permitted on a research-use-only basis. The product is not authorised by the MHRA as a human or veterinary medicine, and purchasers are responsible for compliance with their institutional research-governance framework. Both peptides remain on the WADA Prohibited List under growth factors and growth factor modulators, which affects athlete eligibility separately from criminal law [unverified].

What purity grade is Body Pharm's BPC-157 + TB-500?

Each batch is released against an HPLC purity specification, with the exact percentage and chromatogram disclosed on the batch-specific Certificate of Analysis supplied with the order.

How is the pen stored and for how long?

Store the pen at 2–8 °C, protected from light. Unopened shelf life is 24 months. Once the pen is first pierced (first use), use it within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. The pen is pre-filled, so there is no reconstitution step.

Can I get a certificate of analysis for my batch?

Yes. A batch-matched CoA is issued per pen and is available on request before or after purchase, with batch numbers traceable to the fill-and-seal record.

Does Body Pharm ship to all UK addresses?

Yes. All UK mainland and offshore addresses are served by free tracked Royal Mail despatch, with tracking issued at the point of fulfilment.

What is the difference between buying a blend pen and two separate peptides?

The pen eliminates two reconstitution steps and the mg-to-volume calculation that introduces the largest source of dose variance in vial-based work. For a fuller comparison of the molecules themselves, see BPC-157 vs TB-500: how the two peptides compare.

Next Steps

You now understand how the BPC-157 + TB-500 blend works mechanistically, why a sealed pen reduces dose variance compared to two separate vials, and what the current UK regulatory framework permits for research use. Review the full BPC-157 + TB-500 dosing protocol to confirm the pen fits your study design, then request a batch Certificate of Analysis from our support desk before checkout to verify purity and identity data against your institutional requirements.

Explore More Body Pharm Research Peptides

If your research extends beyond BPC-157 + TB-500, a few adjacent resources may be relevant. The full recovery peptides category groups tissue-repair and regenerative compounds in one place, while the peptide guides hub collates protocol and comparison material. For evaluation-stage readers, BPC-157 vs TB-500: how the two peptides compare and GHK-Cu are the most common next stops alongside the dosing protocol.

References

1. Competitor UK blend product listings (OP Labs, Regen Peptides, Tide Labs; 10 mg total reconstitution vials) and comparative HPLC-purity advertising. Commercial/vendor material; no peer-reviewed primary source; unverified.
2. Competitor UK blend product listings and advertised ≥99% HPLC purity claims on comparable blends. Commercial/vendor material; no peer-reviewed primary source; unverified.
3. Competitor UK blend product listings referenced for format and purity comparison. Commercial/vendor material; no peer-reviewed primary source; unverified.
4. UK regulatory framing under the Human Medicines Regulations 2012 (unlicensed injectable preparations; MHRA position). Regulatory background; no single peer-reviewed primary source; verify current position at gov.uk/mhra; unverified.
5. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. pubmed.ncbi.nlm.nih.gov/22074294
6. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov/40756949